Study reveals a complex interplay of genetic and epigenetic changes in Alzheimer's disease progression

Alzheimer's disease affects more than 6 million people in the United States, and there are very few FDA-approved treatments that can slow the progression of the disease.

Related Keywords

United States ,Vishnu Dileep ,Benjamin James ,Zhuyu Verna Peng ,Manolis Kellis ,Carles Boix ,Danielle Ellis ,Matheus Victor ,Hansruedi Mathys ,Li Huei Tsai ,Xushen Xiong ,Cure Alzheimer Foundation ,Broad Institute ,National Institutes Of Health ,Artificial Intelligence Laboratory ,Picower Institute For ,Artificial Intelligence ,Religious Orders ,Aging Project ,Carles Boix Phd ,National Institutes ,Cure Alzheimer ,Aging ,Lzheimer 39s Disease ,Rain ,Fell ,Dementia ,Na ,Dna Damage ,Drugs ,Gene ,Ene Expression ,Genes ,Enetic ,Enome ,Enomic ,Inflammation ,Laboratory ,Language ,Metabolism ,Icroglia ,Eurodegeneration ,Euron ,Eurons ,Protein ,Research ,Sai ,